Pancreatic cancer screening in patients with presumed branch-duct intraductal papillary mucinous neoplasms

Table 1 Previous studies on prevalence of incidental pancreatic cysts

Article	Country	Design	Method of detection	Population	Prevalence, %
Kimura et al[14], 1995	Japan	Retrospective	Autopsy	300 consecutive autopsies in an elderly population	24.3
Zhang et al[20], 2002	United States	Retrospective	1.5 T MRI	1444 patients who underwent a MRI, including 323 patients performed for pancreatic or biliary indication	19.6
Laffan et al[17], 2008	United States	Retrospective	16-MDCT	2832 16-MDCT performed for nonpancreatic indication	2.6
Lee et al[21], 2010	United States	Retrospective	1.5 T MRI	616 MRI performed for nonpancreatic indication	13.5
Girometti et al[16], 2011	Italy	Retrospective	1.5 T MRI	152 MRI performed for nonpancreatic indication	44.7
Ip et al[18], 2011	United States	Retrospective	CT or MRI*	17443 patients who underwent a CT and 2700 patients who underwent a MRI	CT 2.2, MRI 15.9
Matsubara et al[22], 2012	Japan	Retrospective	1.5 T MRI	1226 MRI performed for nonpancreatic indication	10
Sey et al[23], 2015	United States	Prospective	EUS	341 EUS performed for nonpancreatic indication	9.4
Soroida et al[19], 2016	Japan	Retrospective	US	5198 US performed as part of a general health examination	3.5
Moris et al[10], 2016	United States	Retrospective	1.5 T or 3 T MRI	500 MRI performed for nonpancreatic indication	41.6
Martínez et al[24], 2018	Spain	Prospective	EUS	298 EUS performed for nonpancreatic indication	21.5

*There is no description of the MRI instrument model. CT: Computed tomography; EUS: Endoscopic ultrasonography; MRI: Magnetic resonance imaging; PDAC: Pancreatic ductal adenocarcinoma; US: Ultrasonography.

Table 2 Frequency of concomitant pancreatic ductal adenocarcinoma in patients with branch-duct - intraductal papillary mucinous neoplasm during follow-up

Article	Country	Design	n	Diameter of IPMN in mm*	Follow-up inmo*	Surveillanceinterval	Imaging(optional imaging)	Incidence of concomitant PDAC,n (%)
Kobayashi et al[31], 2005	Japan	Retrospective	47	28.2	41.0	No description	EUS	3 (6.4)
Tada et al[32], 2006	Japan	Prospective	80	22.0	48.0	q6 mo	US, CT, MRI, EUS	2 (2.5)
Uehara et al[7], 2008	Japan	Retrospective	60	No description	87.0	q3-6 mo	US (CT, MRI, EUS)	5 (8.3)
Sawai et al[33], 2010	Japan	Retrospective	103	18.0	59.0	At least yearly	EUS	2 (1.9)
Tanno et al[8], 2010	Japan	Prospective	89	20.0	64.0	q6-12 mo	CT, MRI, EUS	4 (4.5)
Maguchi et al[9], 2011	Japan	Retrospective	349	19.0	44.0	No description	US, CT, MRI, EUS, ERCP	7 (2.0)
Ohno et al[34], 2012	Japan	Retrospective	142	22.3	42.5	q6 mo	CE-EUS, CT	5 (3.5)
Sahora et al[35], 2013	United States	Retrospective	411	16.0	60.0	q3-24 mo	CT, MRI	3 (0.7)
Kamata et al[36], 2014	Japan	Retrospective	102	No description	42.0	q3 mo	US, CT, MRI, EUS	7 (6.9)
Malleo et al[37], 2015	Italy	Prospective	569	18.0	56.0	At least yearly	MRI (EUS)	3 (0.5)

*Mean, or, if not available, median or midpoint of range. CT: Computed tomography; EUS: Endoscopic ultrasonography; MRI: Magnetic resonance imaging; PDAC: Pancreatic ductal adenocarcinoma; IPMN: Intraductal papillary mucinous neoplasm; US: Ultrasonography.